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Abstract
Recent analyses of the whole genome sequencing data enable us to predict cancer inci-
dence for healthy people at present. In addition, metabolome analyses rediscovered that 
“cancer is a metabolic disease”. Importantly, it has been suggested that mitochondrial 
dysfunction might precede the metabolic change. In this chapter, we would discuss if 
“cancer is a transcriptional disease”. Analyzing 5′-upstream non-protein-encoding 
regions of the human mitochondrial function-associated genes, we speculate that mito-
chondrial functions could be recovered or improved at a transcriptional level. In the near 
future, novel chemo-/gene-therapies might be applied to treat cancer patient converting 
cancerous cells into normal differentiated cells.
Keywords: cancer, CTCF (CCCTC-binding factor), DNA repair, ETS (E26 transformation 
specific), gene expression, GGAA, HMGB (High mobility group box), ISG (Interferon 
stimulated gene), metabolism, mitochondria, NAD+, PARP inhibitors, poly (ADP-ribosyl)
ation, PARP (poly(ADP-ribose) polymerase), transcription, transcription factors, Warburg 
effect
1. Introduction
We have already learned that “cancer is a genetic disease”. Recent high-impact research has 
shown the genomic/genetic differences between cancer and normal cells using methods 
such as next-generation sequencing [1, 2]. The analysis of the whole genome sequencing 
data will even enable us to predict the incidence of cancer in healthy individuals [3]. More 
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importantly, recent metabolome analyses have led to the rediscovery that metabolites could 
be biomarkers for cancer and its development [4]. The “Warburg effect”, which was shown by 
Dr Otto Warburg over 60 years ago, is the most essential discovery in the field of cancer 
science [5]. The “Warburg effect” refers to abnormal metabolism in cancer, which mainly 
utilizes glucose to produce ATP by glycolysis. In this regard, “cancer is a metabolic dis-
ease”. This is not only important as an indicator of tumors, but also as one of the essen-
tial characteristics of cancer [6, 7]. A number of lines of evidence, including dysregulated 
TCA (Krebs/Citrate)-cycle progression and the insufficient oxidative phosphorylation in 
cancer cells, suggest that mitochondrial dysfunction might precede the metabolic change 
[8]. Thus, “cancer must be a mitochondrial disease”. In this chapter, which focuses on 
the causative factors that lead to mitochondrial dysfunction, we discuss whether “cancer 
is a transcriptional disease”. Most of the genes (99%) that encode mitochondria or their 
function-associated proteins are contained in nuclear genomes [9]. The mitochondrial 
functions might be recovered or improved at a transcriptional level. In this chapter, we 
propose the establishment of novel chemo-/gene-therapies with no side effects, to force 
cancerous cells to regenerate into their normal differentiated state.
2. The relevance of duplicated GGAA-motifs in the 5′-upstream regions 
of human genes to the regulation of biological events
2.1. The transcription factors that recognize and bind to the GGAA-containing motifs
The most widely known transcription factors (TFs) that selectively recognize the GGAA-core-
containing sequences are the ETS (E26 transformation specific) family proteins, which con-
sist of at least 27 members [10, 11]. Moreover, a genome-wide ChIP-seq analysis estimated 
that the promoter regions of human genes are very frequently occupied by ETS family or 
GGAA-binding proteins [12]. The duplication of the GGAA-motif could be advantageous 
to organisms, as it would allow the transcription of various genes to be controlled in a man-
ner that is mainly dependent on the expression profile of the GGAA-binding proteins in the 
cells [13, 14]. Besides ETS family proteins, several TFs could bind to the motif. For example, 
some of the duplicated GGAA-motifs would be identical to IFN-stimulated response ele-
ment (ISRE), the consensus sequence of which is 5′-GGAAANNGAAACT-3′ [15], if one of 
the Ns was G. The double-stranded sequence, 5′-AACTTT-3′, which is a core binding motif 
of the IRF1 [16], could be generated if CT was inserted between GGAA and TTCC. Moreover, 
NF-κB p65 (RELA) homodimer binds to two symmetric sequences, 5′-GGAATTTCC-3′ and 
5′-GGAATTCCC-3′ [17]. IRF8 (ICSBP) either positively or negatively regulates transcription 
through binding to ISRE [18, 19].
Importantly, the ETS family proteins and other TFs cooperatively regulate the expression of vari-
ous genes. For instance, STAT1 plays a role in the regulation of the expression of interferon (IFN)-
stimulated genes (ISGs) with ETS family proteins [20, 21]. Sp1 and Ets1 interact with each other 
to regulate mouse Npr1 gene expression [22]. The ETS-binding consensus sequence is frequently 
found with a second ETS-binding sequence and with the Sp1-binding sequence, but not with a 
TATA element [23], implying the exclusive role of the GGAA- and TATA elements. The human 
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VEGFR1 promoter region, which contains overlapping GGAA-motifs, is also regulated by CREB 
and EGR-binding elements [24]. Furthermore, the mouse Ppp2r1a gene promoter, which carries 
duplicated TTCC motifs, is regulated by Creb, Ets1, Ap2 alpha, and Sp1proteins [25]. Thus, multi-
ple elements adjacent to duplicated GGAA-motifs may recruit various TFs to form a pre-initiation 
complex on the transcription start site (TSS) of TATA-less promoters. The transcription initiation 
system might be advantageous for a rapid response to stresses in a TATA-independent manner.
2.2. The duplicated GGAA-motifs that are contained in the 5′-upstream regions of 
immune response factor-encoding human genes
Duplicated GGAA-motifs are found in the 5′-upstream of the ISGs [20, 26, 27]. The GGAA-
motifs are also harbored in the IFN-stimulated response element (ISRE)-like sequences [28, 29]. 
Thus, the duplicated GGAA-motifs near TSSs may play roles in controlling the expression of 
ISGs. The ISG-encoded proteins include TFs, immune modulators, apoptosis mediators, and 
anti-viral factors [30]. Previously, the duplicated GGAA-motifs in the regulatory regions of ISGs 
have been analyzed [31]. We surveyed the 5′-upstream regions in a number of ISGs to find 
GGAA-motifs within 500-bp upstream from the TSSs [32], and reported that IFNβ-inducible 
human OAS1 promoter activity is regulated by binding of ELF-1 (which belongs to the ETS fam-
ily proteins) to a duplicated GGAA-motif, and by its interaction with Sp1 and Rb proteins [33].
Collectively, the majority of the promoter regions from ISGs contain duplicated GGAA-motifs 
but rarely with TATA element. This suggests that the mechanism by which transcription is initi-
ated differs from that of the house-keeping genes or genes that are essentially required, such 
as those that encode cell structure components. IFNs, the expression of which should be sup-
pressed under normal conditions, only play important roles when it is necessary to fight against 
viral infection and oncogenesis. The duplicated GGAA-motifs might have contributed, through 
evolution, to the development of an immune response at the transcriptional level. In addition, 
GGAA-binding factors, which are associated with other TFs around TSSs, facilitate the expres-
sion of each ISG as appropriate, depending on the different signals that are induced by IFN.
2.3. The duplicated GGAA-motifs in the 5′-upstream regions of the human DNA repair 
factor-encoding genes
The duplicated GGAA (TTCC) motif is present adjacent to the TSS of the human TP53 gene 
[34], the expression of which is regulated by IFN-α and β [35]. IRF1 was reported to be a 
negative regulator of the human TERT promoter in response to IFN-γ [36]. In addition, IRF-5 
has been shown to upregulate the expression of DNA repair/apoptosis-associated genes [37]. 
Moreover, DNA damage initiates an immune response that regulates DNA repair-associ-
ated genes [38]. These observations suggest that the immune responses and DNA damage 
responses might be co-dependent, and that the duplicated GGAA-motifs have important 
roles in controlling the expression of genes that encode DNA repair-associated factors in 
response to IFN-induced signals.
It should be noted that the duplicated GGAA-motif is present in the promoter regions of the 
human Poly(ADP-ribose) polymerase 1(PARP1) [39, 40] and XRCC1 [41] genes. The duplicated 
GGAA-motifs are present near the TSS of the ADPRHL2 (ARH3) and the ZC3HAV1 genes, 
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which encode mitochondria-localizing poly(ADP-ribose) (PAR) degrading enzyme [42] and 
an anti-viral RNA-binding protein PARP13 [43, 44], respectively. These findings suggest that 
the expression of genes encoding single-strand DNA break repair factors is commonly regu-
lated by the duplicated GGAA-motifs.
The promoter activities of the human WRN and TERT genes, both encoding telomere mainte-
nance factors, positively respond to both 2-deoxy-d-glucose (2DG) [45] and trans-resveratrol 
(Rsv) [46], which are caloric restriction (CR) mimetic drugs that have been shown to prolong 
the life span of several organisms [47]. The natural compound Rsv upregulates the expression 
of the HELB gene [46, 48], which encodes DNA replication and DNA double strand break 
repair-helicase HELB (HDHB) [49–52]. Moreover, the 5′-regulatory regions of the genes that 
encode DNA repair factors, such as XPB, RB1, RTEL1, ATR, TP53, and CDKN1A (p21), contain 
GGAA duplications near the TSS [53]. Several of the DNA repair factors are localized in the 
mitochondria and may also regulate the mitochondrial functions [53].
2.4. The surveillance of regulatory regions adjacent to the TSSs of human mitochondrial 
function-associated genes
The surveillance of a human genomic DNA database suggested putative TPA-responsive ele-
ments in the 5′-upstream regions of the MRPL32, NDUFB3, NDUFS3, SDHB, and SDHAF2 
genes contain GGAA duplication [54]. The duplicated GGAA-motifs are present in the 
upstream regions of human genes encoding mitochondrial ribosomal proteins and enzymes 
or components that function in the TCA cycle and oxidative phosphorylation (OXPHOS) [54].
Mitochondrial dysfunction is thought to cause either cellular senescence or oncogenesis 
[55–58]. Remarkably, TCA cycle enzymes, fumarate hydratase (FH), and succinate dehydro-
genase (SDH) have been suggested as tumor suppressors [59]. Hence, mutations of the TCA 
cycle factor-encoding genes give rise to abnormal mitochondrial respiration, which is one of 
the characteristics of tumors and cancer [60, 61]. Mutations of the IDH1 and IDH2 genes have 
been identified in human brain cancer cells [62, 63]. A recent study demonstrated that the 
mutation of IDH2 could lead to the generation of sarcoma [64]. Duplicated GGAA-motifs are 
contained in the upstream region of the NAMPT (NmPRT), encoding a nicotinamide phos-
phoribosyltransferase that catalyzes the first rate-limiting step of (nicotinamide adenine dinu-
cleotides) NAD+ synthesis from nicotinamide [65–67]. Depending on the NAD+ level, NAMPT 
could modulate the TCA cycle, poly(ADP-ribosyl)ation, and sirtuin-mediated de-acetylation 
[66, 67]. The duplicated GGAA-motifs are present near the TSSs of the human TCA cycle 
enzyme-encoding ACLY, ACO2, CS, FH, IDH1, IDH3A, IDH3B, SDHAF2, SDHB, SDHD, and 
SUCLG1 genes [68].
A duplicated GGAA-motif is present in the bidirectional promoter of the PDHX [54], which 
encodes one of the components of the PDH enzyme to metabolize pyruvate to acetyl-
CoA. Aberrant pyruvate metabolism is thought to play a prominent role in cancer [69]. The 
genomic deletion of ME2, which encodes malic enzyme 2 (an NAD+-dependent malate decar-
boxylase that converts malate into pyruvate), is found in pancreatic ductal adenocarcinoma 
[70]. The GGAA-duplication is not only found near the TSSs of the human ME2 gene, but 
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also the MDH2 gene (which encodes NAD+-dependent malate dehydrogenase), suggesting 
that duplicated GGAA-dependent transcription could affect the metabolism of malate in the 
mitochondria.
3. The possible roles of metabolic states that can alter transcription 
profiles
Recently, a study using a CAP-SELEX analysis showed that different transcription factors, 
such as FOXO1 and ETS family proteins, are mediated by a DNA that contains a GGAA-
core motif [71]. As described above, a number of promoters or regulatory regions of human 
genes that encode immune response-/DNA repair-/mitochondrial function-associated pro-
teins contain overlapping or duplicated GGAA-containing motifs. Thus, the alteration of the 
profile of the GGAA-motif-binding proteins or their associated protein factors may allow 
for the control of appropriate cellular responses against viral infection, DNA damage, and 
oxidative/nutrient/metabolic stress. Importantly, the DNA damage responses affect the tran-
scriptional state [72] through oxidative stress, which is mainly produced by the mitochondria 
[73, 74]. NF-κB- and p53-dependent transcription, which regulates the expression of the ISGs 
and DNA repair factor-encoding genes, is also affected by oxidative stress [75]. Thus, metabo-
lites that are mainly produced by respiration or mitochondrial functions may influence the 
transcription control system [76, 77].
3.1. The transcription profile may be controlled by the NAD+/NADH balance
We have reported that the promoter regions of the human TP53, HELB, and telomere main-
tenance factor-encoding genes respond positively to Rsv [46, 48, 78]. Rsv not only activates 
SIRT1, which is an NAD+-dependent deacetylase [79], but also inhibits phosphodiesterase 
[80]. Importantly, low-dose Rsv activates mitochondrial complex I [81] to upregulate the 
NAD+/NADH ratio, to induce the expression of duplicated GGAA-motif-driven genes. The 
transcription of the bidirectional promoter-driven BRCA1/NBR2 genes, which contain a 
duplication of the GGAA-motif, may be regulated by the NAD+/NADH ratio [82]. Notably, 
the C terminal-binding protein (CtBP) [83, 84] has a central role in this regulation as a 
metabolic sensor. Moreover, PARP1 poly(ADP-ribosyl)ates transcription elongation fac-
tor NELF to release the paused RNA pol II-dependent transcription [85], suggesting that 
PARP1 itself contributes to NAD+-sensitive transcription. Recently, it was reported that 
nuclear PAR can be utilized by NUDIX5 to supply ATP molecules, which are required for 
chromatin remodeling [86]. Thus, the accumulation of NAD+ molecules or NAD+/NADH 
ratio-sensitive proteins, including GGAA-motif binding TFs, might affect the transcrip-
tion of ISGs/DNA repair/mitochondrial function-associated genes in response to metabolic 
stress.
It should be noted that PARP activity is upregulated in tumors and cancer cells [44]. Because 
the duplicated GGAA-motifs are present in the 5′-upstream regions of the human PARP and 
PARG genes [40], subtle changes in the quality/quantity profile of the GGAA-binding TFs may 
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modulate the PAR synthesis/degradation ratio at the transcription level. The accumulation of 
NAD+ molecules in cells might be transiently caused by mitochondrial dysfunction, which 
is usually accompanied by insufficient OXPHOS or aberrant respiration [87, 88]. However, 
when DNA damage eventually activates PARP, NAD+ molecules will be consumed to syn-
thesize PAR polymer in the nuclei or mitochondria. Thus, the decrease in the NAD+/NADH 
ratio would not only reduce the activities but also the expression of enzymes that function 
in the NAD+-dependent TCA cycle progression. At this point, cells will have to produce ATP 
in a mitochondria-independent manner. This metabolic change would be observed as the 
“Warburg effect” in cancer cells [5, 6].
3.2. The regulation of TFs and nucleotide binding proteins by poly(ADP-ribosyl)ation
PARP inhibitors, such as talazoparib, niraparib, rucaparib, olaparib, and veliparib, are clini-
cally used for the treatment of cancer, especially when BRCA1 and BRCA2 gene mutations 
are present [89]. They all interact with the NAD+-binding site of the catalytic domain of 
PARP1 and PARP2. A recent study indicated that the NAD+-binding pocket of the PARP1 
regulates interaction with DBC1, which is deleted in breast cancer 1, which is a known SIRT1 
inhibitor protein [90]. A decrease in the NAD+ will upregulate the interaction between DBC1 
and PARP1, leading to the suppression of its activity. This might partly explain why DNA 
repair declines with aging [91]. The poly(ADP-ribosyl)ation of proteins not only initiates 
the response to DNA damage, but also regulates the transcription of specific genes [92]. 
The poly(ADP-ribosyl)ation of C/EBPβ by PARP-1 modulates its transcriptional activity 
to enhance the expression of the genes encoding factors that regulate adipogenesis [93]. A 
recent study showed that the poly(ADP-ribosyl)ation of an RNA-binding protein HuR by 
PARP1 stabilizes Cxcl2 gene transcripts [94]. Moreover, the poly(ADP-ribosyl)ation of FoxO3 
suppresses its transcriptional activity and leads to cardiac hypertrophy [95]. Taken together, 
poly(ADP-ribosyl)ation, which consumes NAD+ as a substrate for PAR synthesis, may regu-
late transcription to respond to DNA damage-induced signals. Thus, it should be noted that 
PARP inhibitors not only limit the DNA damage response to lead to the death of cancerous 
cells, but also reduce the consumption of NAD+ molecules to modulate the transcription of 
specific genes.
4. Epigenetic alterations in chromosomal DNAs and proteins
Epigenetic alterations are frequently found in cancer, implying that “cancer is an epigen-
etic disease” [96]. It has been hypothesized that epigenetic and/or transcriptional changes 
play a role in determining the chromatin state in tumor cells [97]. Epigenetic regulation is 
mainly driven by modifications of chromosomal DNAs and histone proteins [98]. The bio-
logical relevance between cellular metabolites and the gene expression has been proposed 
as the RNA/enzyme/metabolite (REM) networking system [99]. The metabolites, NAD+, 
S-adenosylmethionine (AdoMet), and acetyl-CoA, are the substrates for poly (ADP-ribosyl)
ation, methylation, and acetylation, respectively [76], suggesting that these metabolic state-
dependent molecules play important roles in the epigenetic regulation.
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4.1. The possible functions of poly(ADP-ribosyl)ation on epigenetic regulation
NAD+ not only plays important roles in DNA repair, mitochondrial functions, and cellular senes-
cence [72, 100], but also affects the modification of chromatin proteins [77] and modulates the 
gene expression regulatory system [101]. More importantly, NAD+ is a substrate for the PARP 
enzyme to synthesize PAR macromolecules, which modify both PARP itself and chromosomal 
proteins and DNA repair factors [67]. Histones and HMGB (High mobility group box) proteins 
can be poly(ADP-ribosyl)ated [102–105], suggesting that modifications by such macromolecules 
on chromosomes affect the epigenetic regulation of the gene expression system. Moreover, 
poly(ADP-ribosyl)ation on the chromosomal insulator protein CTCF (CCCTC-binding factor) 
may be involved in epigenetic regulation [106, 107]. Recently, it was shown that CTCF binds 
directly to PAR to be recruited at DNA lesion sites, indicating that the CTCF also plays a role in 
the DNA damage response [108]. It has been suggested that poly(ADP-ribosyl)ation affects the 
methylation patterns in chromosomal DNAs [109, 110]. A recent study showed that the tran-
scriptional regulation of the EZH2 gene, which encodes the catalytic subunit of the polycomb 
repressive complex 2 (PRC2), by PARP1 [111], affects the methylation of chromatin proteins 
[112]. Because the incidence of cancer increases with aging [113], a decline in the cellular level of 
NAD+, which might accompany the decrease in PARP activity [114]. SIRT1, which depends on 
the NAD+ molecule to de-acetylate histone proteins, plays important roles in the aging process 
[115]. Taken together, these observations imply that NAD+ and its polymerized form, PAR, are 
involved in epigenetic regulation, and that it may be altered in line with the aging process.
4.2. The DNA methylation of chromosomal DNAs
The methylation of promoter regions of specific genes in human chromosomes can be used 
as biomarkers in various cancers [116]. The DNA methylation reaction is catalyzed by meth-
yltransferases (DNMTs), which utilize AdoMet as a methyl group donor [117]. A recent study 
showed that intragenic DNA methylation, which is carried out by Dnmt3b in mouse embry-
onic stem cells, protects the gene body from the entry of spurious RNA pol II and the ini-
tiation of cryptic transcription [118]. The extended data showed that the ETS factor binding 
regions are sensitive to the knock out of the Dnmt3b gene, suggesting that the occupation 
of the GGAA (TTCC)-motifs by GGAA-motif binding proteins could be epigenetically con-
trolled by methylation. Furthermore, the regulation of demethylation by ten-eleven translo-
cation (TET)-family enzymes [119], the activity of which is reduced by hypoxia, should not 
be ignored. Hypoxia-induced hyper methylation has been demonstrated to occur on the pro-
moter regions of the DNA repair factor-encoding genes, including BRCA1, FANCD2, FANCF, 
POLL, and UNG [120]. Of note, the duplicated GGAA-motifs are contained in these gene pro-
moters [53]. A methylation sensitive SELEX analysis showed that ETS-binding was inhibited 
by mCpG, though NFAT, which also recognizes the GGAA-core motif sequence and preferen-
tially binds to methylated DNA [121]. The observation suggests that GGAA-motif recogniz-
ing TFs could be classified into two groups according to their preference to DNA methylation.
The SET protein is an epigenetic regulatory factor that promotes loss of methylation through 
direct interaction with hypo-acetylated histones [122]. A genome-wide analysis showed that 
DNA hypermethylation is apparently induced in old male adults, relative to young male 
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adults, suggesting a relationship between DNA methylation and aging [123–125]. Moreover, 
the methylation and demethylation of the lysine residues of histones might affect the regula-
tion of transcription [126]. In summary, AdoMet, a methyl group donor, plays an important 
role in epigenetic control.
4.3. The acetylation of histones could regulate the generation or progression of cancers
Acetyl-CoA is required for acetylation on the lysine residue of histones [127]. This process 
is catalyzed by acetyltransferases (HATs), including KAT2A (GCN5), KAT2B (CAF), KAT5 
(ESA1), KAT7 (HBO1), and KAT8 (MOF) [128], which can be classified into two major groups: 
the GCNT and MYST families [129]. At least 11 enzymes are known to be histone deacetylases 
(HDACs) [130]. Because the increased or aberrant expression of HDACs has been reported in 
various cancers, inhibitors or modulators of HDACs are expected to be effective as antican-
cer drugs [131]. On the other hand, the lysine acetylation is negatively regulated by sirtuin 
proteins, including SIRT1 [116], which de-acetylate proteins, utilizing NAD+ as an acceptor 
of the acetyl group [127]. It is hypothesized that a reduction in nutrient levels could induce 
the accumulation of NAD+ to activate sirtuins. Histone de-acetylation is consistent with the 
finding that CR mimetics prolong the life span [131–133]. In cancer cells, if mitochondrial dys-
function occurs with a reduction in the NAD+ level or the hindrance of the progression of the 
TCA cycle, acetyl-CoA might only be converted to citrate to be used as an acetyl group donor 
for histones in the nuclei. If so, an increase in histone acetylation would occur naturally in the 
course of oncogenesis. The activation of HDACs in cancer cells might be the response to the 
aberrant hyper-acetylation of histone proteins that could lead to the abnormal transcription 
of various genes, including the mitochondrial function-associated genes.
To summarize, key metabolites, NAD+ and acetyl-CoA could regulate DNA methylation and 
histone acetylation directly or indirectly, and play essential roles in epigenetic control.
5. Mitonuclear communication regulates apoptosis, DNA repair, 
and  aging
The mechanisms by which nuclear DNA damage signaling causes the mitochondrial dysfunc-
tions that accelerate aging and aging-related diseases including cancer have been investigated 
in a review [134]. This process can be referred to as “mitonuclear communication” [135], sug-
gesting that DNA repair systems are integrated into the mitochondrial functions. Given that α 
proteobacteria are the putative ancestors of the mitochondria [136], they need to take care of the 
nuclear DNAs that contain almost all (99%) of their essential protein-encoding genes [9]. Thus, 
the mitochondria might have developed a nuclear genome monitoring system, especially when 
DNA damage is induced. Several TCA cycles or metabolic enzymes functions as tumor sup-
pressors [59, 64, 137], suggesting that mitochondrial dysfunction may lead to cancerous states.
5.1. The mitochondria play the role of judge in the decision to induce cell death
The execution of apoptosis is mediated by the mitochondria in response to various stresses, 
including DNA damage and immunological stress signals [138–140]. Thus, the mitochondria 
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are known to serve as master regulators of danger signaling to determine cell death or sur-
vival [141]. Several mechanisms, including the regulation of the regulators of apoptosis 
[142, 143] and miRNAs [144], are involved in the induction of apoptosis. The surveillance of 
the human genomic DNA database indicated the presence of the duplicated GGAA-motifs 
in the 5′-regulatory regions of the human PDCD1, DFFA, BCL2, FAS, FASL, ATG12/AP3S1, 
APOPT1/BAG5, and HTRA2/AUP1 genes [13, 53, 54]. These observations suggest that the 
expression of the apoptosis regulating factor-encoding genes is modulated by the GGAA-
duplicated sequences. In this context, apoptosis or programmed cell death, which is con-
trolled by the mitochondria, partly depends on the GGAA-motif binding TFs.
5.2. The localization of p53 and other DNA repair factors in the mitochondria and the 
regulation of their gene expression
Recent studies have shown that the p53 protein not only acts as a “guardian of the genome”, 
but also serves as a regulator of metabolism [145, 146]. Moreover, p53 has been reported to 
accumulate in the mitochondria in response to stress [147]. Besides p53, a number of widely 
known DNA repair factors, including ATM, BRCA1, PARP, PARG, and RB, localize in the 
mitochondria or regulate their functions [148–152]. The surveillance of the 5′-upstream 
regions of these DNA repair factor-encoding genes revealed that they commonly possess 
duplicated GGAA-motifs [53, 78].
GGAA-motif duplications are found in the bidirectional APEX1/OSGEP promoter region. The 
APEX1 encodes apurinic/apyrimidinic endonuclease 1 (APE1) that regulates both the base exci-
sion repair (BER) and the mitochondrial DNA repair systems [75, 153]. The GGAA-duplication 
is contained in the regulatory region of the head–head configured ACO2/PHF5A genes [54]. The 
ACO2 gene encodes aconitase, which plays an important role in the TCA cycle to produce citrate 
and isocitrate, and which also serves as a mitochondrial redox-sensor [154]. Importantly, aconi-
tase and mitochondrial BER enzyme OGG1 (8-oxoguanine DNA glycosylase) cooperatively pre-
serve mitochondrial DNA integrity [155]. We also confirmed that the duplicated GGAA-motifs 
were present in the 5′-upstream regions of the genes associated with Fanconi’s anemia (FA) [53], 
which encode the DNA repair factors that are shown to regulate nucleotide excision repair and 
genome stability [156]. Interestingly, it was shown that mitochondrial dysfunction forces FA 
cells to produce energy by glycolysis [157], suggesting that FA proteins might be involved in 
the metabolic switch system in cancer cells. Additionally, Cockayne syndrome proteins CSA 
and CSB, which play roles in nucleotide excision repair (NER), accumulate in the mitochondria 
under oxidative stress [158]. In KRAS/LKB1-mutant lung cancer cells, carbamoyl phosphate 
synthetase-1 (CPS1), which is localized in mitochondria and which eliminates NH
4
 to initiate the 
urea cycle, also plays a role in controlling the pyrimidine/purine balance to regulate the integrity 
of nuclear DNAs [159]. In this circumstance, the silencing of the CPS1 gene expression leads to 
an incomplete S-phase or apoptotic cell death due to increased DNA damage. As expected, the 
duplicated GGAA is present in the CPS1/LANCL1 bidirectional promoter region. However, no 
such element is found near the TSSs of either the CAD or ASS1 genes, which encode cytoplasmic 
enzymes carbamoyl phosphate syntetase-2 and argininosuccinate synthase, respectively. These 
observations suggest that expression of the mitochondria-localizing, DNA repair-associated 
protein-encoding genes could be cooperatively regulated by duplicated GGAA-motif binding 
TFs, supporting the hypothesis that mitochondrial dysfunction causes oncogenesis [8].
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5.3. The communication between telomeres and mitochondria may depend on the 
NAD+/ NADH ratio
The telomeres and mitochondria are thought to communicate with each other [160]. Several 
nuclear DNA repair factors play roles in the maintenance of mtDNAs, and damaged mtDNAs 
in turn exert signals to regulate nuclear transcription [74]. The system by which DNA repair/
energy production is monitored might be mediated by the balance of the NAD+/NADH ratio, 
which is regulated by a number of enzymes in the nuclei, mitochondria, and cytosol [161]. 
In breast cancer cells, the crosstalk between BRCA1 and PARP1 maintains the stability of the 
DNA repair ability, which would be partly sensitive to the NAD+ concentration [162].
The mitochondria might have conveniently deposited their function-associated genes into the 
nuclei, but need to take care, especially when DNA damage occurs. However, high-dose or 
repeated DNA damage may eventually activate the PARP enzyme, which consumes NAD+ as 
a substrate for the synthesis of PAR, to initiate the DNA repair system [66]. The decrease in 
the NAD+ level will subsequently cause incomplete TCA cycle progression and the dysregu-
lation of respiration/OXPHOS, accompanied by the reduced expression of the mitochondrial 
function-associated genes. At this stage, the “Warburg effect” can be observed (Figure 1).
Figure 1. Toward the establishment of a novel cancer therapy. Cellular NAD+ molecules will decrease in accordance with 
aging or increased levels of various types of stress, especially DNA damage, which activates the PARP enzyme, which 
synthesizes PAR to consume NAD+ as a substrate. Subsequently, alterations in the transcriptional profile might occur, 
leading to a reduction or the mismanagement of the mitochondrial functions. In these circumstances, energy producing 
mitochondrial respiratory systems will decline or be dysregulated, while glycolysis will be enhanced providing 
ATP molecules that allow cells to proliferate in an unrestricted manner. Novel cancer therapies should be based on 
the concept that they will never kill cancer cells; rather, they should force the cells to regain their normal respiratory 
systems, including the TCA cycle and OXPHOS. The recovery of these mitochondria might also lead to the restoration 
of the mitonuclear communication system. In order to establish a gene therapy, it is necessary to reveal the molecular 
mechanisms that control the transcription of the mitochondrial function-associated genes.
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6. The involvement of nicotinamide adenine dinucleotide (NAD+) in 
oncogenesis and the aging process
The biological relevance of the NAD+ molecule, especially in relation to its pivotal roles in 
metabolism and the protection of chromosomal DNAs, has been discussed in detail [66, 67]. A 
recent study showed that nuclear PAR can be utilized by NUDIX5 to supply ATP molecules, 
which are required for chromatin remodeling [86]. Moreover, NAD+ and its precursor nicotin-
amide have been reported to ameliorate metabolism or the mitochondrial functions [163–165].
The repletion of NAD+ improves the mitochondrial functions to prolong the life span of adult 
mouse stem cells [166]. Conversely, decreased concentrations of NAD+ could cause aging or 
aging-related diseases [75]. These observations suggest that the NAD+ level may be correlated 
with mitohormesis [167], and that nutrient sensing molecules may control aging [57].
6.1. NAD+ restricts the generation and development of cancer by supporting the 
mitochondrial functions
Several drugs that induce an increase in the intracellular NAD+ level are expected to con-
tribute to the establishment of novel therapeutics for treating age-related diseases, includ-
ing cancer [168]. Mitochondrial dysfunction has been suggested to be associated with the 
development of tumors or cancerous cells [169, 170]. In breast cancer cells, the knockdown 
of the subunit NDUFV1 leads to an aberration in complex I, which was shown to enhance 
aggressiveness or metastasis [171]. An increase in the cellular level of NAD+ may be associ-
ated with the improvement of the mitochondrial integrity to suppress oncogenesis. PGC-1α, 
which upregulates mitochondrial biogenesis, drives NAD+ biosynthesis and thereby induces 
stress resistance [172]. A recent study showed that PGC-1α suppresses the metastasis of mela-
noma, acting on the transcription program, namely the PGC-1α-ID2-TCF-integrin axis [173].
A loss of CSB, which can localize in the mitochondria [158], activates PARP1 to synthesize 
PAR [174], suggesting that the dysregulation of the mitochondrial functions to regulate DNA 
repair system may reduce the NAD+/NADH molecular ratio.
6.2. NAD+-dependent transcription of DNA repair factor-encoding genes
It is worth noting again that the NAD+ molecule is the substrate for the PARP enzyme, which 
is required for the DNA damage response and the DNA repair system [66, 67]. The inhibition 
of the PARP1 enzyme ameliorates the mitochondrial metabolism through the activation of 
SIRT1 [175]. Conversely, the over-activation of the PARP1 enzyme can lead to mitochondrial 
dysfunction [176]. The PARP1 gene expression was found to be negatively regulated when 
poly(ADP-ribose) glycohydrolase (PARG) siRNAs were introduced into HeLa S3 cells [40], 
suggesting that the degradation of the PAR macromolecule is required for the transcription of 
the PARP1 gene. Because the 5′-upstream regions of both the human PARP1 and PARG genes 
commonly contain the duplicated GGAA-motifs [53, 54], these two genes may be regulated 
by an NAD+-sensitive mechanism. The results support the concept that PARP1 is involved in 
the NAD+-sensitive transcription system [85]. In summary, the NAD+/NADH ratio not only 
contributes to the DNA repair, but also to the fine-tuning of the transcription of genes that 
encode the NAD+ metabolism-associated DNA repair factors.
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As described previously, the promoter regions of a number of genes that encode TCA cycle 
enzymes and DNA repair factors contain duplicated GGAA (TTCC) motifs [53, 54]. Thus, the 
fine-tuning of the transcription of mitochondrial function-associated factor- and DNA repair 
factor-encoding genes would be required for cells to conduct mitochondria in response to 
DNA damage-inducing stress.
7. The development of novel cancer therapeutics to improve 
mitochondrial functions
In cancer cells, the mitochondrial functions are downregulated but glycolysis is upregulated 
[7, 8]. Thus, inhibitors of glycolysis/PDHK1/PARP, which target the metabolic switch in cancer 
cells, could be effective anti-cancer drugs [59]. In general, glycolysis- or glycolytic pathway-
targeting drugs are expected to kill cancer cells specifically. For example, 2-deoxy-d-glucose, 
cisplatin and 5-FU—which have an inhibitory effect on glycolysis—are used to treat cancer in 
the clinical setting [177]. However, glycolysis is one of the most essential biological reactions. 
Thus, glycolysis inhibitors may be harmful or toxic to normal cells. Given that mitochondrial 
dysfunction is another essential cause of oncogenesis, the improvement of the mitochondria 
might provide clues that can be used to design innovative next-generation cancer therapies.
7.1. Chemicals that will initiate the recovery of mitochondria
Our previous in vitro studies showed that Rsv moderately upregulates the expression of vari-
ous duplicated GGAA-motif-driven genes, including TP53 and HELB [46, 48, 78]. Given that 
the increase in the NAD+/NADH ratio can improve the mitochondrial functions, the introduc-
tion of the redox reaction-associated genes may be applied in cancer treatment. PARP inhibi-
tors, which are especially effective for treating cancer with BRCA1 and BRCA2 mutations by 
disrupting specific types of DNA repair systems, are clinically approved drugs [89]. Another 
compound is TEMPOL, an antioxidant that has a suppressive effect on tumor cell prolif-
eration [178], which increases the cellular NAD+ level, supporting the DNA repair system 
[179, 180]. A number of compounds that target mitochondria have been tested in clinical trials 
[181]. Tocotrienols and their analogues target mitochondria and the immune system, caus-
ing the death of cancer cells [182]. Metformin and rapamycin are also expected to be novel 
anti-cancer/aging drugs that effectively suppress mTOR signaling [183]. Activators of mTOR, 
AMPK, and PGC-1α have been shown to have a synergistic effect with PD-1 blockade therapy 
[184], suggesting that mitochondrial activation can augment the immune response.
7.2. Possible gene-therapies that improve the mitochondrial functions
PGC-1α, which is encoded by the PPARGC1A gene, has been shown to be involved in the de 
novo synthesis of the NAD+ [172]. Recently, it was reported that lactamase β (LACTB) is a mul-
tifunctional protein, which suppresses tumors through its effects on the mitochondrial lipid 
metabolism [185]. LACTB is included in mitochondrial complex I and treatment of fibroblast 
cells with its siRNA reduces complex I activity [186]. It therefore works as an upregulator 
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of NAD+. As expected, multiple duplications of the GGAA-motif are present in the bidirec-
tional promoter region between the LACTB (MRPL56) gene and the bidirectional partner 
LOC107987798. We confirmed that the duplicated GGAA-motif is present near the TSS of 
the human PDSS2 gene, which encodes prenyl-diphosphatase synthase subunit 2, which is 
a modulator of the complex I–III and II–III [133]. The PDSS2 is required for the integrity of 
Coenzyme Q (CoQ) or ubiquinone, which can improve the mitochondrial functions [187]. 
Thus, PDSS2 would be one of the targets for novel anticancer agents [188, 189]. The introduc-
tion of the LbNOX gene, which encodes bacterial NADH oxidase, into HeLa cells via a lentivi-
ral vector ameliorates the proliferative and metabolic defects caused by the impairment of the 
electron transport chain (ETC) [190].These lines of evidence suggest that NAD+ metabolism 
regulator encoding genes, including PARP, PARG, and NAMPT, as well as the PPARGC1A, 
LACTB, PDSS2, and LbNOX genes, could be applied or targeted in anti-cancer gene therapy.
Alternatively, TF-encoding genes can be applied to anti-cancer therapies that aid in the recov-
ery of mitochondria. First, the transcription modulator CtBP might be artificially controlled 
to suppress oncogenesis or cancer progression [83, 84]. Second, because duplicated GGAA-
motifs are present in the 5′-upstream regions of a number of DNA repair factor- and mitochon-
drial factor-encoding genes, GGAA-motif binding factors could upregulate the mitochondrial 
functions at the transcriptional level. Recently, it was reported that mouse Gabp, which is 
an ETS family protein, is required for mitochondrial biogenesis through the regulation of 
the Tfb1m gene [191], suggesting that a GABP expression vector might be designed and con-
structed for cancer treatment. The 5′-upstream regions of a number of human genes contain 
the GGAA-duplication, and it is a GC-box that is very frequently found near the GGAA-core 
motif [12]. Recently, it was reported that mutations on the ETS family protein-encoding ERF 
and ERG genes play roles in prostate oncogenesis [192], implying that imbalances in GGAA-
binding TFs could lead to aberrant gene expression. In order to determine which TF-encoding 
genes should be chosen, the mechanisms through which each of these genes is differently 
regulated during tumorigenesis should be elucidated.
8. Conclusions and future prospects
In this article, we focused on the transcription mechanism that regulates the mitochondrial 
functions and the DNA repair systems, both of which decline with aging. Although the molec-
ular mechanisms underlying the regulation of the expression of these genes are not yet fully 
understood, several lines of evidence suggest that it is dependent on the NAD+/NADH balance.
The anti-cancer drugs that are currently in use, including metabolism inhibitors, telomerase 
inhibitors, and apoptosis inducers, were developed with the common intention of killing can-
cer cells. Although immune receptor target drugs have been applied in the clinical setting, 
they are similar in that they force cancer cells to die. The anti-cancer drugs that are currently 
in use damage both malignant cancer cells and normal healthy cells. Importantly, the unde-
sired effects of these anti-cancer drugs are problematic with regard to the quality of life (QOL) 
of cancer patients, especially those who are too old to endure severe adverse effects that occur 
during the course of chemotherapy. In order to avoid lethal side effects, individual whole 
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genome sequencing to identify drug sensitivities, the development of a side-effect monitoring 
system, and the improvement of treatment policies could be adapted. These are the burdens 
that are necessitated by the intrinsic concept underlying the development and creation of 
most anti-cancer drugs.
In the near future, novel anti-cancer drugs or therapies must be developed and established. 
These drugs should not kill cancer cells; rather they should give them a chance to regain 
the right mitochondrial functions and DNA repair systems, and immunological responses. 
Natural or chemical compounds can ameliorate the NAD+/NADH level to improve the mito-
chondrial functions, DNA repair systems, and even immune responses. Alternatively, specific 
TF expression vector(s) could be introduced into cancer cells to lead them to recover to a 
healthy state. A number of promoter regions of the mitochondrial function-, DNA repair-, 
and anti-viral/tumor factor-encoding genes have duplicated GGAA-motifs with GC-boxes. 
Needless to say, it is necessary to determine the TFs that should and should not be applied 
prior to their clinical use. Based on this novel concept, the design of anticancer/tumor drugs or 
gene transfer vector(s) will contribute to the prevention of aging and its associated diseases, 
including cancer.
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